Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | FLT3 inhibitors as a strategy to treat AML

Charles Craddock • 5 Apr 2019
EBMT 2019
Acute Myeloid Leukemia Leukemia Midostaurin Quizartinib Sorafenib

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses the promising role of FLT3 inhibitors for FLT3-mutated acute myeloid leukemia (AML). Mentioning the encouraging survival outcomes in patients treated with agents such as midostaurin, quizartinib and sorafenib, Prof. Craddock also reports the potential of FLT3 inhibitors as being effective maintenance therapies post-transplant. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Charles Craddock

Strategies to reduce relapse risk post-transplant in AML
11:48
Strategies to reduce relapse risk post-transplant in AML
Charles Craddock • 19 Sep 2026
Expanding donor access for allogeneic transplantation in AML
2:46
Expanding donor access for allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026
Allogeneic transplantation in fit older adults with AML
1:34
Allogeneic transplantation in fit older adults with AML
Charles Craddock • 19 Sep 2026
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
1:35
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals